ConductScience.org, home

Paper36710948

Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.

Salvaris R and 8 others. Blood Cell Ther, 2022. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients. Papers, record 36710948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36710948

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evaluating the Efficacy, Toxicity and Pharmacokinetic Profile of Oral Busulfan in Allogeneic Stem Cell Transplant Patients.
PubMed
Journal
Blood Cell Ther
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2023-02-02
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salvaris RRoss
2Salman SSam
3O'Halloran SSean
4Joyce DDavid
5Mathew NNavin
6Cooney JJulian
7Wright MMatthew
8Cannell PPaul
9Purtill DDuncan

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124218510Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.Clin Cancer Res2014https://conductscience.org/library/papers/24218510PubMed
224810613Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.Eur J Clin Pharmacol2014https://conductscience.org/library/papers/24810613PubMed
323394705
Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.
J Hematol Oncol2013https://conductscience.org/library/papers/23394705PubMed
412374452Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/12374452PubMed
530372796Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.J Intern Med2019https://conductscience.org/library/papers/30372796PubMed
622406655
Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children: the results of a population pharmacokinetic study from a large pediatric cohort undergoing hematopoietic stem-cell transplantation.
Ther Drug Monit2012https://conductscience.org/library/papers/22406655PubMed
78599861Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy.Cancer Chemother Pharmacol1996https://conductscience.org/library/papers/8599861PubMed
830511436Effect of glutathione S-transferase genetic polymorphisms on busulfan pharmacokinetics and veno-occlusive disease in hematopoietic stem cell transplantation: A meta-analysis.Basic Clin Pharmacol Toxicol2019https://conductscience.org/library/papers/30511436PubMed
921105791Reduced mortality after allogeneic hematopoietic-cell transplantation.N Engl J Med2010https://conductscience.org/library/papers/21105791PubMed
1018215782High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.Biol Blood Marrow Transplant2008https://conductscience.org/library/papers/18215782PubMed
119108427Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.Blood1997https://conductscience.org/library/papers/9108427PubMed
1224744269Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.Blood2014https://conductscience.org/library/papers/24744269PubMed
1320711242Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.Bone Marrow Transplant2011https://conductscience.org/library/papers/20711242PubMed
1421918171Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.Clin Cancer Res2011https://conductscience.org/library/papers/21918171PubMed
1523129746Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.J Clin Oncol2013https://conductscience.org/library/papers/23129746PubMed
1615255794What is the best size descriptor to use for pharmacokinetic studies in the obese?Br J Clin Pharmacol2004https://conductscience.org/library/papers/15255794PubMed
1722615660Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation.Daru2011https://conductscience.org/library/papers/22615660PubMed
1812374454
Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.
Biol Blood Marrow Transplant2002https://conductscience.org/library/papers/12374454PubMed
1916133536Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study.Cancer Chemother Pharmacol2006https://conductscience.org/library/papers/16133536PubMed
2016785066
Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Biol Blood Marrow Transplant2006https://conductscience.org/library/papers/16785066PubMed

See all 25 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GSTK1373156PubTator's text mininghttps://conductscience.org/library/genes/373156

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36710948

GET https://conductscience.org/api/papers/v1/36710948/references?page=2